27940380|t|Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma
27940380|a|Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single - targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA -based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen - specific aAPC -based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination treatment also acted synergistically in an in vivo murine melanoma model to result in delayed tumor growth and extended survival, while either treatment alone had no effect. This was shown mechanistically to be due to decreased PD-1 expression and increased antigen - specific proliferation of CD8+ T cells within the tumor microenvironment and spleen. Thus, biomaterial -based therapy can synergize with other immunotherapies and motivates the translation of biomimetic combinatorial treatments.
27940380	36	60	antigen presenting cells	T017	UMLS:C0003315
27940380	76	89	PD-1 blockade	T103	UMLS:C3883362
27940380	99	107	melanoma	T038	UMLS:C0025202
27940380	145	158	immune system	T022	UMLS:C0020962
27940380	175	195	anti-tumor responses	T038	UMLS:C1516031
27940380	223	243	cancer immunotherapy	T058	UMLS:C0278348
27940380	331	350	physical parameters	T033	UMLS:C0449381
27940380	359	364	shape	T082	UMLS:C0332479
27940380	369	373	size	T082	UMLS:C0456389
27940380	401	418	immune-modulators	T103	UMLS:C0005525
27940380	531	546	immunotherapies	T058	UMLS:C0021083
27940380	562	581	targeted approaches	T058	UMLS:C2985566
27940380	648	652	PLGA	T103	UMLS:C0071599
27940380	671	694	antigen presenting cell	T017	UMLS:C0003315
27940380	696	700	aAPC	T017	UMLS:C0003315
27940380	708	727	checkpoint blockade	T038	UMLS:C3544497
27940380	738	772	anti-PD1 monoclonal antibody (mAb)	T103	UMLS:C4289970
27940380	793	800	antigen	T103	UMLS:C0003320
27940380	812	816	aAPC	T017	UMLS:C0003315
27940380	824	834	activation	T038	UMLS:C1326120
27940380	839	852	anti-PD-1 mAb	T103	UMLS:C4289970
27940380	853	872	checkpoint blockade	T038	UMLS:C3544497
27940380	894	909	IFN-γ secretion	T038	UMLS:C3156720
27940380	913	925	CD8+ T cells	T017	UMLS:C0242629
27940380	936	957	Combination treatment	T058	UMLS:C0009429
27940380	991	998	in vivo	T082	UMLS:C1515655
27940380	999	1005	murine	T103	UMLS:C0591833
27940380	1006	1014	melanoma	T038	UMLS:C0025202
27940380	1015	1020	model	T170	UMLS:C3161035
27940380	1091	1100	treatment	T058	UMLS:C0087111
27940380	1176	1180	PD-1	T103	UMLS:C3883362
27940380	1206	1213	antigen	T103	UMLS:C0003320
27940380	1225	1238	proliferation	T038	UMLS:C0596290
27940380	1242	1254	CD8+ T cells	T017	UMLS:C0242629
27940380	1293	1299	spleen	T017	UMLS:C0037993
27940380	1307	1318	biomaterial	T103	UMLS:C0005479
27940380	1326	1333	therapy	T058	UMLS:C0087111
27940380	1359	1374	immunotherapies	T058	UMLS:C0021083
27940380	1419	1443	combinatorial treatments	T058	UMLS:C0009429